Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Acquired by Barclays PLC

Barclays PLC boosted its holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) by 189.1% in the third quarter, HoldingsChannel.com reports. The firm owned 61,997 shares of the company’s stock after buying an additional 40,551 shares during the quarter. Barclays PLC’s holdings in Acumen Pharmaceuticals were worth $154,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Acumen Pharmaceuticals in the 3rd quarter valued at $44,000. American Century Companies Inc. lifted its position in Acumen Pharmaceuticals by 31.3% in the second quarter. American Century Companies Inc. now owns 45,444 shares of the company’s stock valued at $110,000 after acquiring an additional 10,840 shares during the last quarter. Rhumbline Advisers acquired a new position in Acumen Pharmaceuticals in the second quarter valued at $127,000. Murchinson Ltd. purchased a new position in shares of Acumen Pharmaceuticals during the second quarter worth about $136,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Acumen Pharmaceuticals during the second quarter worth about $306,000. 71.01% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Acumen Pharmaceuticals in a research report on Wednesday, November 13th.

Acumen Pharmaceuticals Stock Down 1.1 %

ABOS stock opened at $1.83 on Wednesday. The company has a market cap of $109.95 million, a price-to-earnings ratio of -1.33 and a beta of 0.02. The company has a fifty day moving average price of $2.27 and a 200 day moving average price of $2.52. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 10.43. Acumen Pharmaceuticals, Inc. has a 12 month low of $1.69 and a 12 month high of $5.09.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its earnings results on Tuesday, November 12th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). During the same quarter last year, the firm earned ($0.24) EPS. Sell-side analysts expect that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Insider Buying and Selling at Acumen Pharmaceuticals

In other Acumen Pharmaceuticals news, CEO Daniel Joseph Oconnell sold 47,778 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $1.84, for a total value of $87,911.52. Following the transaction, the chief executive officer now directly owns 454,707 shares of the company’s stock, valued at approximately $836,660.88. The trade was a 9.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 79,508 shares of company stock valued at $146,556 in the last ninety days. Insiders own 7.10% of the company’s stock.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.